Skip to main content

Table 3 The correlation of variables with GVHD incidence in allogeneic HSCT recipients

From: Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia

Variables Severe aGVHD Extensive cGVHD
Incidence (%) r P value Incidence (%) r P value
Gender   0.293 0.134   0.319 0.060
 Male 5/14 (35.7%)    3/14 (21.4%)   
 Female 1/10 (10%)    0/10   
Age, years   0.05 0.807   0.033 0.872
 ≥ 20 2/9 (22.2%)    1/9 (11.1%)   
 < 20 4/15 (26.7%)    2/15 (13.3%)   
Donor-recipient relationship   0.083 0.599   0.055 0.465
 Mother–child 3/12 (25%)    2/12 (16.7%)   
 Father–child 2/5 (25%)    0/5   
 Siblings 1/7 (14.3%)    1/7 (14.3%)   
Patient/donor pair   0.225 0.566   0.541 0.022
 3 HLA loci 3/16 (18.8%)    0/16   
 2 HLA loci 2/6 (33.3%)    2/6 (33.3%)   
 1 HLA loci 1/2 (50%)    1/2 (50%)   
Severe aGVHD      0.364 0.099
 Yes     2/6 (33.3%)   
 No     1/18 (5.6%)   
  1. HSCT hematopoietic stem cell transplantation, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, HLA human leukocyte antigen